

Age at study start (Enter n	umber of years. If only age	categories presented, enter m	ninimum and maximum.)	
☐ Mean	Median	Mnimum	Maximum	
Age at study start not	reported			
Disease severity Met	ric/source used (specify):			
Mild n	8			
Moderate n	8 %			
Mild-moderate n	8 %			
Moderate-severe n	□ %			
Severe n	□ %			
Remission/Inactive n	□ %			
Unknown/missing 🔲 n	□ %			
Disease severity not	reported			
lleal n	8			
lleo-colonic n	8 %			
Colonic n	8 %			
Perianal n	□ %			
Disease location not	reported			
Inflammatory n	■ %			
Stricturing n	■ %			
Penetrating n	■ %			
Disease behavior no Disease activity index	treported	-		
CDAI at randomization (RC	Ts) or study start (cohorts)			
☐ Mean	☐ Median	Mnimum	Maximum	
Pediatric CDAI at randomiz	nation (RCTs) or studystart (c			
☐ Mean	☐ Median	Mnimum	Maximum	
Harvey Bradshaw Index at I	randomization (RCTs) or stud	dy start (cohorts)		
☐ Mean	☐ Median	Mnimum	■ Maximum	
			- Waxindin	
	at randomization (RCTs) or			
Mean	Median	Mnimum	☐ Maximum	Other index (specify):
Disease activity index r	not reported CTs) or study start (cohorts)	¢.		
Mean Mean	☐ Median	Mnimum	☐ Maximum	☐ IBDQ not reported
CRP at randomization (RC	Ts) or study start (cohorts)			
☐ Mean	Median	Mnimum	Maximum	CRP not reported
Diagnosed with Crohn's di	sease (for observational st	udies with an IBD population)	□ n □ %	☐ Not reported
Medications taken by pati	ents <u>DURING</u> the study period	od (Indicate which medications	s then record N, % of patients, i	
Aminosalicylates	2 8	□ n □ %		
Antibiotics		□ n □ %		

Anti-TNF	■ n	■ %	
Corticosteroids	□ n	8	
■ Methotrexate	□ n	■ %	
☐ Thiopurines	□ n	■ %	
Immunomodulators	□ n	■ %	
Other medication (specify):	□ n	■ %	
Other medication (specify):	□ n	□ %	
Other medication (specify):	□ n	□ %	
Other medication (specify):	□ n	□ %	
Medications taken by patients <u>BEFORE</u> the	study period (Indicate w	hich medications then record N, %	of patients, if available)
Aminosalicylates	□ n	□ %	
Antibiotics	□ n	■ %	
☐ Anti-TNF	□ n	□ %	
Corticosteroids	□ n	□ %	
■ Methotrexate	□ n	□ %	
☐ Thiopurines	□ n	■ %	
Immunomodulators	□ n	■ %	
Other medication (specify):	□ n □	■ %	
Other medication (specify):	n	■ %	
Other medication (specify):	□ n	■ %	
Other medication (specify):	□ n	□ %	
Medications taken by patients <u>BEFORE</u> the : N, % of patients, if available)	study period or during th	e run-in period to <u>INDUCE REMISSI</u>	ION (Indicate which medications then record
Aminosalicylates	□ n	□ %	
Antibiotics	□ n	■ %	
☐ Anti-TNF	□ n	□ %	
Corticosteroids	□ n	□ %	
■ Methotrexate	□ n	₽ %	
☐ Thiopurines	□ n	■ %	
Immunomodulators	□ n	□ %	
Other medication (specify):	□ n	□ %	
Other medication (specify):	■ n	₪ %	
Other medication (specify):	□ n	□ %	
Other medication (specify):	□ n	□ %	
Cure medication (specify).			

112. Comments (Limit to 250 characters)	
113. Comments (Limit to 250 characters)	1,
The commonity Lamin to 250 on a detail of	
Submit Form and go to 🔻 or Skip to Next	11